

# Common Fund Concept Clearance: Somatic Cell Genome Editing Program – Phase 2 (Vote)

Philip J. Brooks, Ph.D. Program Coordinator, Office of Rare Diseases National Center for Advancing Translational Sciences

commonfund.nih.gov

### Common Fund Proposal for Translating in vivo Genome Editing Therapies to the Clinic



**Concept Clearance:** Phase 2 Common Fund Program

### **TITLE: Somatic Cell Genome Editing Program (SCGE), Phase 2**

**Objective:** To accelerate the development of genome-editing therapeutic agents by facilitating IND-enabling studies, establishing pathways to regulatory approval, and disseminating successful strategies for initiating first in human clinical trials.

- 1. Improve assays to determine quality, safety and efficacy of editing reagents
- 2. Optimize in vivo candidate genome editing therapeutic candidates toward IND applications
- 3. Demonstrate first in human basket trials for *in vivo* genome editing therapeutics
- 4. Foster collaboration and disseminate new technologies and protocols to the community


**Funds Available** ~\$45M per year for 16 awards

Program Duration: 5 years, FY23-27 (Phase 2)

**Council Action:** Vote on support of Program

# SCGE Phase 2 Concept Clearance - Background

The Common Fund



### Science

Contents -News Careers 🚽

Journals 🗕

în ŧ

26

A new way to modify DNA, "prime editor" couples two enzymes, Cas9 (blue) and reverse transcriptase guide RNA (green) that takes the complex to a specific place on DNA's double helix (yellow and purple) holds the code for an insertion of new DNA at that spot. PEYTON RANDOLPH

### New 'prime' genome editor could surpass CRISPR

### By Jon Cohen | Oct. 21, 2019, 1 nature biotechnology

Contents -

Explore content 
Journal information Publish with us ~

nature > nature biotechnology > articles > article

#### Article | Published: 15 June 2020

**CHANGE-seq reveals genetic and epigenetic effects** on CRISPR-Cas9 genome-wide activity

Cicera R. Lazzarotto, Nikolay L. Malinin, Yichao Li, Ruochi Zhang, Yang Yang, GaHyun Lee, Eleanor Cowley, Yanghua He, Xin Lan, Kasey Jividen, Varun Katta, Natalia G. Kolmakova, Christopher T. Petersen, Qian Qi, Evgheni Strelcov, Samantha Maragh, Giedre Krenciute, Jian Ma, Yong Cheng & Shengdar Q. Tsai 🖂

Science

Careers News

Journals -

Read our COVID-19 research and news.

#### SHARE REPORT

f

in

CRISPR-Cas $\Phi$  from huge phages is a hypercompact genome editor

Datrick Pausch<sup>1,2,\*</sup>, Basem Al-Shayeb<sup>1,3,\*</sup>, Ezra Bisom-Rapp<sup>4</sup>, Connor A. Tsuchida<sup>1,5</sup>, D Zheng Li<sup>6</sup>, B Brady F. Cress<sup>1,2</sup>, <sup>(i)</sup> Gavin J. Knott<sup>1,2,7</sup>, <sup>(i)</sup> Steven E. Jacobsen<sup>6,8</sup>, <sup>(i)</sup> Jillian F. Banfield<sup>1,9</sup>, <sup>(i)</sup> Jennifer A. Doudna<sup>1,2,8,10,11,12,†</sup>

#### nature nanotechnology

**)**ate Explore content Y Journal information Y Publish with us 🗸

nature > nature nanotechnology > letters > article

#### Progr Letter | Published: 09 September 2019

### A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing

Guojun Chen, Amr A. Abdeen, Yuyuan Wang, Pawan K. Shahi, Samantha Robertson, Ruosen Xie, Masatoshi Suzuki, Bikash R. Pattnaik, Krishanu Saha 🖂 & Shaoqin Gong 🖂

Nature Nanotechnology 14, 974–980(2019) Cite this article 15k Accesses | 65 Citations | 156 Altmetric | Metrics

#### nature communications

Explore Content 🗸 Journal Information ~ Publish With Us 🗸

nature > nature communications > articles > article

#### Article | Open Access | Published: 28 October 2019

#### **Engineered amphiphilic peptides enable delivery** of proteins and CRISPR-associated nucleases to airway epithelia

therapies for a val Sateesh Krishnamurthy, Christine Wohlford-Lenane, Suhas Kandimalla, Gilles Sartre, David K. Meyerholz, Vanessa Théberge, Stéphanie Hallée, Anne-Marie Duperré, Thomas Del'Guidice, Jean-Pascal Lepetit-Stoffaes, Xavier Barbeau, David Guay & Paul B. McCray Jr. 🗠

> *Nature Communications* **10**, Article number: 4906 (2019) Cite this article 8996 Accesses | 19 Citations | 61 Altmetric | Metrics

### non Fund

# **SCGE Phase 2 Planning Activities**



Workshop with:

20 subject matter experts from academic, government and industry - April 20, 2021 -

### https://commonfund.nih.gov/editing/meetings



### Consultations with:

SCGE Phase 1 Program Consultants (Drs. Paula Cannon, Kathy High, Vic Myers and Fyodor Urnov) FDA Center for Biologics Evaluation and Research staff (Drs. Ying Huang, Anna Kwilas, and Peter Marks) NIH Leaders of translational programs for genome-based therapies (Drs. Chris Boshoff, NINDS's CREATE-Bio and URGenT; Mike Pieck, NHLBI's Catalyze) DARPA Program Manager for PREPARE (Dr. Amy Jenkins)

Environmental scan of:

*In vivo* genome editing therapeutics in clinical trials Industry genome editing pipelines NIH genome editing therapeutics portfolio

### The Future of *in vivo* Genome Editing is Here



Biotech

# With first-in-human trial results, Intellia shows the world that gene editing has arrived

by Annalee Armstrong Jun 26, 2021 11:15am

NTLA-2001 for ATTR





Editas Medicine Announces Enrollment of the First Pediatric Cohort in the BRILLIANCE Clinical Trial of EDIT-101 for the Treatment of LCA10 Following IDMC Endorsement


June 23, 2021 07:00 ET | Source: Editas Medicine, Inc.

### SCGE Phase 2: Translating *in vivo* Genome Editing Therapies into the Clinic More Broadly & Efficiently The Common Fund



**Consensus needs:** 

Improved assays for assessment of quality, safety and efficacy of editing reagents Support for development and optimization of technologies for candidate genome editing therapeutics Tests of efficient regulatory pathways and *in vivo* genome editing clinical trials





Initiative 1. (U01) Genome Editing Assay Development Deliverable: Multiple improved assays for preclinical studies Impact: Facilitate IND submissions for genome editing

Will support optimization and validation of broadly applicable, IND-enabling assays for experimental genome editing therapeutics

- 3-year technology development phase (U01)
- Includes:
  - Assays for pharm/tox, CMC, on/off-target effects, immune response, cell tracking, etc.



Initiative 2. (U19) Research Programs for Genome Editing Therapeutic Development Deliverable: Multiple approaches to developing genome editing therapeutics for different disease scenarios Impact: IND packages ready for future gene editing clinical trials

Will support the optimization and characterization of experimental in vivo genome editing therapeutics though INDenabling studies

- 5-year awards
- Broad-based, multidisciplinary approach to genome editing therapy development
- Each research program targeting multiple diseases in same tissue or cell type
- Activities to support IND submissions of multiple projects as needed, e.g., pharm tox, CMC, off-target assays



Initiative 3. (UG3/UH3) Demonstrate Efficient Clinical Trial Strategy for Platform Genome Editing Clinical Trials Deliverable: Demonstration of streamlined regulatory pathway toward IND approval for *in vivo* genome editing trials of >1 disease at a time


Impact: Efficiencies in preclinical data generation, regulatory submissions, and clinical trial design

Will support IND-enabling studies and basket clinical trials demonstrating the platform nature of genome editing technologies

- 3-year preclinical phase (UG3) and 2-year clinical stage (UH3)
- Same delivery vehicle, same editor, multiple guides and diseases
- Required consultations with FDA thru INTERACT and pre-IND meetings
- Activities include pharm/tox, CMC, clinical trial planning, clinical trials

# SCGE Phase 2 Proposed In. 4





Initiative 4. (U24) Dissemination and Coordinating Center Deliverable: Broad dissemination of strategies for regulatory submissions Impact: Accelerate and improve IND submissions for genome editing

Will support data sharing, technical, and regulatory support in therapeutic development

- Semi-annual meetings
- Data and protocol sharing within the consortium and broader community

# SCGE Phase 2 supports the NIH mission and meets the CF criteria



**Transformative**: Must have high potential to dramatically affect biomedical and/or behavioral research over the next decade

SCGE Phase 2 will de-risk multiple approaches to developing *in vivo* genome editing therapeutics, and make these approaches widely and publicly available, thereby accelerating clinical trials of therapies for new disease indications.

**Catalytic**: Must achieve a defined set of high impact goals within a defined period of time SCGE Phase 2 will establish Proof of Concept and support platform tools and experiences that will be broadly shared.

**Synergistic**: Outcomes must synergistically promote and advance individual missions of NIH ICs to benefit health SCGE Phase 2 will synergize with and build upon ongoing studies supported by NIH, as well as industry

**Cross-cutting**: Program areas must cut across missions of multiple NIH ICs, be relevant to multiple diseases or conditions, and be sufficiently complex to require a coordinated, trans-NIH approach The deliverables from this program can be applied to a variety of genetic diseases, spanning multiple NIH ICs.

Unique: Must be something no other entity is likely or able to do

High-risk and highly impactful projects will be de-risked within the program infrastructure. SCGE Phase 2 is designed to support multidisciplinary teams, stakeholder engagement and delivery of publicly available tools.



### Facilitating Clinical Trials of Genome Editing for Multiple Diseases

In. 1: Fit for regulatory purpose assays for e.g., pharm/tox, CMC, on/off-target effects, immune response, and *in vivo* tracking of edited cells.

In. 2: Datasets to support multiple gene editing INDs targeting different diseases in different cell types

In. 3: A template for obtaining an IND and running a clinical genome editing trial of more than one disease at a time, which explicitly leverages the inherent platform capacity of genome editors

In. 4: Identification and dissemination of best practices and the most successful approaches from the projects supported by SCGE Phase 2.

# **SCGE Phase 2 Proposed Budget**



The Common Fund

Initiative	Title	# Awards	FY23	FY24	FY25	FY26	FY27	
1	Assay Dev	4 x 2	\$2.0M	\$2.0M	\$4.1M	\$2.0M	\$2.0M	
2	Research Programs	5	\$25.0M	\$25.0M	\$25.0M	\$25.0M	\$25.0M	
3	Clinical Trial Efficiencies	2	\$10.0M	\$20.0M	\$20.0M	\$12.0M	\$12.0M	
4	Coordination	1	\$2.0M	\$2.0M	\$2.0M	\$2.0M	\$2.0M	
RMS		0	0	\$0.25M	\$0.25M	\$0.25M	\$0.25M	
Total			\$39.0M	\$49.3M	\$51.4M	\$41.3M	\$41.3M	\$222M

# **SCGE Phase 2 Planning Committee**



Program Chair: Joni Rutter, PhD, Acting Director, NCATS

Common Fund Program Leader: Mary Ellen Perry, PhD, OSC/DPCPSI/OD

Working Group Coordinator: PJ Brooks, PhD, NCATS

Project Team Leads: PJ Brooks, PhD, NCATS

Colin Fletcher, PhD, NHGRI Oleg Mirochnitchenko, PhD, ORIP/DPCPSI/OD Betty Poon, PhD, NIAID Tatjana Atanasijevic, PhD, NIBIB

### SCGE Working Group and Phase 2 Planning Committee Members

Olivier Blondel, PhD, NIDDK Eric Brunskill, PhD, NIDDK Bonnie Burgess-Beusse, PhD, NIDDK Emily Carifi, PhD, NIAMS Tom Cheever, PhD, NINDS Sean Garin, NHGRI Allison Gillaspy, PhD, NHLBI Daniel Gossett, PhD, NIDDK Patricia Greenwel, PhD, NIDDK Linda Griffith, MD, PhD, NIAID Min He, PhD, NCI W. Keith Hoots, MD, NHLBI Subhashini Jagu, PhD, NCI Chamelli Jhappan, PhD, NCI Marrah Lachowicz-Scroggins, PhD, NHLBI Tim LaVaute, PhD, NINDS Nicholas Leake, MS, OSC/DPCPSI/OD J. Jerry Li, MD, PhD, NCI Guoying Liu, PhD, NIBIB Nicole Lockhart, PhD, NHBI Nicole Lockhart, PhD, NHGRI James Luo, PhD, NHLBI Martha Lundberg, PhD, NHLBI Kyung Moon, PhD, NHLBI Nasrin Nabavi, PhD, NIAID Sonynka Ngosso, MS, MBA, OSC/DPCPSI/OD Lisa Neuhold, PhD, NEI Margaret Ochocinska, PhD, NHLBI David Panchision, PhD, NIMH Aaron Pawlyk, PhD, NICHD Pankaj Qasba, PhD, NICHD Pankaj Qasba, PhD, NHLBI David Rampulla, PhD, NIBIB Les Reinlib, PhD, NIEHS John Satterlee, PhD, NIDA Grace Shen, PhD, NEI Wendy Wang, PhD, NCI George Zubal, PhD, NIBIB

Working Group Program Analyst: Deanna Portero, NCATS